Significance of eosinophil cationic proteins during immunotherapy with interleukin-2 in renal cancer

F. Tacconi; E. Mainardi; M. Deamici; C. Bianchessi; E. Bobbio Pallavicini

Significance of eosinophil cationic proteins during immunotherapy with interleukin-2 in renal cancer

F. Tacconi, E. Mainardi, M. Deamici, C. Bianchessi, E. Bobbio Pallavicini

IRCCS Fondazione Policlinico San Matteo

Research output: Contribution to journal › Article › peer-review

Abstract

Eosinophil cationic proteins are able to damage tissues and cells and contribute to the development of cardiovascular lesion in patients with hypereosinophilic syndrome. Eighteen patients with renal cell carcinoma treated with subcutaneous injection of interleukin-2 and interferon-α developed marked secondary eosinophilia (mean value: pretreatment 448 x 10.3/μl; posttreatment 1933 x 10.3/μl). The state of activation and granule protein release from eosinophil granulocytes were analyzed (in serum and cultures) to evaluate their role in cancer patients and to determine whether a correlation with immunological response exists. Patients were subsequently classified as responders (complete, partial or stable), nonresponders (progression of disease), or as adjuvants to this therapy. Statistically significant high eosinophil cationic protein (p

Original language	English
Pages (from-to)	13-17
Number of pages	5
Journal	International Journal of Immunotherapy
Volume	16
Issue number	1-2
Publication status	Published - 2000

ASJC Scopus subject areas

Immunology
Immunology and Allergy

Fingerprint Dive into the research topics of 'Significance of eosinophil cationic proteins during immunotherapy with interleukin-2 in renal cancer'. Together they form a unique fingerprint.

Cite this

@article{30b53f3e608141b6b479d7d1f4a06ff5,

title = "Significance of eosinophil cationic proteins during immunotherapy with interleukin-2 in renal cancer",

abstract = "Eosinophil cationic proteins are able to damage tissues and cells and contribute to the development of cardiovascular lesion in patients with hypereosinophilic syndrome. Eighteen patients with renal cell carcinoma treated with subcutaneous injection of interleukin-2 and interferon-α developed marked secondary eosinophilia (mean value: pretreatment 448 x 10.3/μl; posttreatment 1933 x 10.3/μl). The state of activation and granule protein release from eosinophil granulocytes were analyzed (in serum and cultures) to evaluate their role in cancer patients and to determine whether a correlation with immunological response exists. Patients were subsequently classified as responders (complete, partial or stable), nonresponders (progression of disease), or as adjuvants to this therapy. Statistically significant high eosinophil cationic protein (p ",

author = "F. Tacconi and E. Mainardi and M. Deamici and C. Bianchessi and {Bobbio Pallavicini}, E.",

year = "2000",

language = "English",

volume = "16",

pages = "13--17",

journal = "International Journal of Immunotherapy",

issn = "0255-9625",

publisher = "Bioscience Ediprint Inc.",

number = "1-2",

}

TY - JOUR

T1 - Significance of eosinophil cationic proteins during immunotherapy with interleukin-2 in renal cancer

AU - Tacconi, F.

AU - Mainardi, E.

AU - Deamici, M.

AU - Bianchessi, C.

AU - Bobbio Pallavicini, E.

PY - 2000

Y1 - 2000

N2 - Eosinophil cationic proteins are able to damage tissues and cells and contribute to the development of cardiovascular lesion in patients with hypereosinophilic syndrome. Eighteen patients with renal cell carcinoma treated with subcutaneous injection of interleukin-2 and interferon-α developed marked secondary eosinophilia (mean value: pretreatment 448 x 10.3/μl; posttreatment 1933 x 10.3/μl). The state of activation and granule protein release from eosinophil granulocytes were analyzed (in serum and cultures) to evaluate their role in cancer patients and to determine whether a correlation with immunological response exists. Patients were subsequently classified as responders (complete, partial or stable), nonresponders (progression of disease), or as adjuvants to this therapy. Statistically significant high eosinophil cationic protein (p

AB - Eosinophil cationic proteins are able to damage tissues and cells and contribute to the development of cardiovascular lesion in patients with hypereosinophilic syndrome. Eighteen patients with renal cell carcinoma treated with subcutaneous injection of interleukin-2 and interferon-α developed marked secondary eosinophilia (mean value: pretreatment 448 x 10.3/μl; posttreatment 1933 x 10.3/μl). The state of activation and granule protein release from eosinophil granulocytes were analyzed (in serum and cultures) to evaluate their role in cancer patients and to determine whether a correlation with immunological response exists. Patients were subsequently classified as responders (complete, partial or stable), nonresponders (progression of disease), or as adjuvants to this therapy. Statistically significant high eosinophil cationic protein (p

UR - http://www.scopus.com/inward/record.url?scp=0034530604&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0034530604&partnerID=8YFLogxK

M3 - Article

AN - SCOPUS:0034530604

VL - 16

SP - 13

EP - 17

JO - International Journal of Immunotherapy

JF - International Journal of Immunotherapy

SN - 0255-9625

IS - 1-2

ER -

Significance of eosinophil cationic proteins during immunotherapy with interleukin-2 in renal cancer

Abstract

ASJC Scopus subject areas

Other files and links

Cite this